Cross-Linked β-Cyclodextrin Nanoparticles for Pulmonary TB Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tuberculosis, particularly multi-drug resistant TB, face challenges with patient compliance, inefficiency, severe side effects, and low cure rates due to the development of drug-resistant strains, necessitating a more effective and localized treatment approach.
Innovation Solution
The use of cross-linked β-cyclodextrin nanoparticles (pβCD) as both drug carriers and intrinsic antibacterial agents, which interfere with lipid rafts in macrophages to impair M. tuberculosis colonization and induce apoptosis, thereby reducing bacterial burden in the lungs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-TB drugs are administered orally, then systemic coverage is achieved, but patient compliance deteriorates due to long treatment duration and severe side effects
Solution Approach 1:
The treatment approach is segmented into local pulmonary delivery and systemic administration, allowing the most effective drugs to be delivered directly to the infection site while reducing overall dosage and treatment duration
Solution Approach 2:
Cross-linked β-cyclodextrin nanoparticles serve as intermedi carriers that enable targeted delivery of anti-TB drugs to pulmonary macrophages, improving drug accumulation at the infection site while reducing systemic exposure and side effects
2Adaptability or versatility
If multidrug-resistant TB is treated with second-line antibiotics, then treatment coverage is expanded, but cure rates deteriorate due to drug resistance and severe side effects
Solution Approach 1:
The cross-linked β-cyclodextrin nanoparticles possess intrinsic antibacterial properties that actively interfere with lipid rafts in macrophages to impair M. tuberculosis colonization and induce bacterial apoptosis, enabling the carrier itself to contribute to treatment efficacy
Solution Approach 2:
The system combines cross-linked β-cyclodextrin polymer with anti-TB drugs to create composite nanoparticles that exhibit both carrier functions and intrinsic antibacterial activity, providing synergistic effects against drug-resistant strains
3Reliability
If local administration of anti-TB drugs is implemented, then treatment efficacy is improved, but device complexity increases due to need for pulmonary delivery systems
Solution Approach 1:
The cross-linked β-cyclodextrin nanoparticles perform multiple functions simultaneously: they serve as drug carriers, exhibit intrinsic antibacterial activity, and can be administered through simple inhalation or injection routes, eliminating the need for complex delivery devices
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
pβCD nanoparticles demonstrate significant reduction in mycobacterial load in lungs, offering a therapeutic benefit comparable to first-line drugs like isoniazid, with potential as standalone antibacterial agents and efficient drug carriers for TB treatment.
Implementation Method 1
pβCD hamper colonisation of macrophages by Mtb by interfering with lipid rafts
Implementation Method 2
pβCD provoke macrophage apoptosis leading to depletion of infected cells
Data Source
AI summary
Multi-drug resistant tuberculosis (TB) is a major public health problem concerning about half a million cases each year. Patients hardly adhere to the current strict treatment consisting of more than 10,000 tablets over a 2-year period. There is a clear need for efficient and better-formulated medications. The inventors have previously shown that nanoparticles made of cross-linked poly-β-cyclodextrins (pβCD) are efficient vehicles for pulmonary delivery of powerful combinations of anti-TB drugs. Here, they report that in addition to be efficient drug carriers, pβCD nanoparticles are endowed with intrinsic antibacterial properties. Indeed, empty pβCD are able to impair M. tuberculosis (Mtb) establishment after pulmonary administration in mice. pβCD hamper colonisation of macrophages by Mtb by interfering with lipid rafts, without inducing toxicity. Moreover, pβCD provoke macrophage apoptosis leading to depletion of infected cells, thus creating a lung micro-environment detrimental to Mtb persistence. Taken together, the results suggest that materials made of cross-linked β-cyclodextrins (e.g. nanoparticles) loaded or not with antibiotics play an antibacterial action by its own and could be used as carrier in drug regimen formulations effective against TB.